Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 16 Jun, 07:07 pm
ExxonMobil (NYSE: XOM) Stock: Why Analysts Are Bullish Despite Short-Term Headwinds ExxonMobil received a 'Buy' upgrade from Bank of America Securities (NYSE: BAC), signaling positive future performance. The company's strategic, low-cost assets in Guyana and active exploration ef
Domo, Inc. (NASDAQ: DOMO) Faces Liquidity Pressure as Strategic Transaction Talks Advance Domo, Inc. reported fiscal first-quarter 2027 revenue of $79.4 million , slightly below analyst expectations, as the company continues to operate in a difficult software market. The company
Citigroup (NYSE: C) has downgraded Payoneer Global Inc. (NASDAQ: PAYO) stock to a Neutral rating from Buy. The downgrade follows the announcement of an all-cash acquisition by Nuvei (NASDAQ: NVEI) , valued at $2.75 billion , or $7.40 per share. An investor rights law firm is inve
High Tide Inc. (NASDAQ: HITI) exceeded analyst expectations for Q2 2026 earnings , reporting a positive EPS of $0.01 against an anticipated loss. The company achieved record revenue of $179.30 million , significantly surpassing forecasts, driven by strong Canadian cannabis retail
Chief Compliance Officer Harmer Derek recently sold 20,000 shares of Accel Entertainment, Inc. (NYSE:ACEL) stock for $260,000 , though he retains a significant holding of 187,827 shares . Despite this insider sale, Accel Entertainment, Inc.'s stock has shown robust performance, h
Dave & Buster's Entertainment (NASDAQ:PLAY) reported disappointing Q1 financial results, missing both EPS and revenue estimates. The company experienced a significant 5.4% decline in comparable store sales, impacting overall revenue. Dave & Buster's Entertainment (NASDAQ:
Analysts anticipate Richtech Robotics to report an EPS of -$0.03 and revenue of $2.38 million for the upcoming quarter. The company is actively expanding its market presence through product showcases, such as the ADAM food service robot, and strategic infrastructure investments,
BTIG has significantly raised its price target for Spyre Therapeutics to $112 , indicating a potential 34% upside for investors. Spyre's experimental drug, SPY002, achieved its primary and secondary endpoints in a Phase 2 trial for inflammatory bowel disease, demonstrating signif
PDD Holdings Inc. (NASDAQ: PDD) received an "Underperform" rating from Exane BNP Paribas, indicating a potential for lower returns compared to the overall market. The company is currently under a securities fraud investigation by Glancy Prongay & Murray LLP, raising significant r
Anticipated Earnings Decline: Analysts project a significant year-over-year decrease in both earnings per share (EPS) and revenue for the upcoming quarter. Valuation Metrics: The company currently holds a trailing price-to-earnings (P/E) ratio of 31.09 and a price-to-sales ratio
Regentis Biomaterials Ltd. surged over 500% on news of European surgeon training for its GelrinC® product, targeting a significant U.S. market. Horizon Quantum Holdings Ltd. and Cuprina Holdings experienced substantial gains, driven by quantum computing expansion and regainin
A merger investigation significantly impacted Fox Corporation's stock performance. Unusual options trading activity led to a steep decline for LifeVantage Corporation. Concerns surrounding pre-IPO investment strategies contributed to the fall of Fundrise Growth Tech Fund, LLC. To
Roku (NASDAQ: ROKU) is currently the target of a significant acquisition by Fox Corporation, aiming to reshape the television industry landscape. Analyst firm KeyBanc downgraded Roku's stock from "Overweight" to "Sector Weight," reflecting a less bullish outlook on the company's
Jabil is strategically positioned in high-growth sectors like AI infrastructure and healthcare , expanding its partnerships in advanced technologies. The company is set to release its quarterly earnings report on June 17, 2026, with analysts estimating an EPS of $3.09 and revenue
Stoke Therapeutics' capital efficiency is assessed by comparing its Return on Invested Capital (ROIC) to its Weighted Average Cost of Capital (WACC). Despite a negative ROIC, common for clinical-stage biopharma companies, Stoke Therapeutics' ROIC/WACC ratio stands at -4.63 . Stok
D.A. Davidson analyst increased TripAdvisor's price target to $15.50 from $10.50 , indicating a potential upside of approximately 18.41% . The positive outlook stems from TripAdvisor's strategic sale of its restaurant booking platform, TheFork, to American Express for $700 millio
An analyst from Barclays lowered their price target on Fox Corporation (NASDAQ: FOXA), reflecting a more cautious investment outlook . Investors reacted negatively to Fox Corporation's plan to acquire Roku Inc. (NASDAQ: ROKU) , primarily due to concerns over new debt and potentia
Market Headwinds: Tesla faces significant challenges including slowing deliveries and intense pricing wars, leading to skepticism about its future growth trajectory. Ambitious Project Risks: The company's ambitious ventures like robotaxis and AI, including the Optimus robot, are
Headlines provided by Investing.com